Background: Noncompliance is a major problem for patients with a psychotic disorder. Two important risk factors for noncompliance that have a severe negative impact on treatment outcomes are impaired illness insight and lack of motivation. Our cross-sectional study explored how they are related to each other and their compliance with depot medication. Methods: Interviews were conducted in 169 outpatients with a psychotic disorder taking depot medication. Four patient groups were defined based on low or high illness insight and on low or high motivation. The associations between depot-medication compliance, motivation, and insight were illustrated using generalized linear models. Results: Generalized linear model showed a significant interaction effect between motivation and insight. Patients with poor insight and high motivation for treatment were more compliant (94%) (95% confidence interval [CI]: 1.821, 3.489) with their depot medication than patients with poor insight and low motivation (61%) (95% CI: 0.288, 0.615). Patients with both insight and high motivation for treatment were less compliant (73%) (95% CI: 0.719, 1.315) than those with poor insight and high motivation. Conclusion: Motivation for treatment was more strongly associated with depot-medication compliance than with illness insight. Being motivated to take medication, whether to get better or for other reasons, may be a more important factor than having illness insight in terms of improving depot-medication compliance. Possible implications for clinical practice are discussed

Additional Metadata
Keywords Depot medication, Illness insight, Motivation, Noncompliance, Psychotic disorder, Schizophrenia
Persistent URL dx.doi.org/10.2147/NDT.S97883, hdl.handle.net/1765/90477
Journal Neuropsychiatric Disease and Treatment
Citation
Noordraven, E.L, Wierdsma, A.I, Blanken, P, Bloemendaal, A.F.T, & Mulder, C.L. (2016). Depot-medication compliance for patients with psychotic disorders: The importance of illness insight and treatment motivation. Neuropsychiatric Disease and Treatment, 12, 269–274. doi:10.2147/NDT.S97883